Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Aslan Pharma Pays $129 Million for Global Rights to Lead Asset

publication date: Jan 3, 2018

Aslan Pharma of Singapore acquired global rights to varlitinib, its lead candidate aimed at several solid tumor cancers, from Array BioPharma in a $129 million agreement. In 2011, Aslan originally acquired rights to varlitinib through proof-of-concept stage. At that point, Aslan planned to partner the drug to a third party, with Aslan and Array splitting the proceeds. Now, Aslan will own full commercialization rights to varlitinib with two payments of $12 million, plus $105 million of milestones and tiered low double-digit royalties on varlitinib sales. More details....

Stock Symbols: (TT: 6497) (NSDQ: ARRY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.